Polymer Drugs in the Clinical Stage(English, Hardcover, unknown)

Polymer Drugs in the Clinical Stage(English, Hardcover, unknown)

  • unknown
Publisher:Springer Science & Business MediaISBN 13: 9780306474712ISBN 10: 0306474719

Paperback & Hardcover deals ―

Amazon IndiaGOFlipkart ₹ 3182SnapdealGOSapnaOnlineGOJain Book AgencyGOBooks Wagon₹12,362Book ChorGOCrosswordGODC BooksGO

e-book & Audiobook deals ―

Amazon India GOGoogle Play Books GOAudible GO

* Price may vary from time to time.

* GO = We're not able to fetch the price (please check manually visiting the website).

Know about the book -

Polymer Drugs in the Clinical Stage(English, Hardcover, unknown) is written by unknown and published by Springer Science+Business Media. It's available with International Standard Book Number or ISBN identification 0306474719 (ISBN 10) and 9780306474712 (ISBN 13).

Proceedings of the International Symposium on Polymer Therapeutics - Recent Progress in Clinics and Future Prospects, held July 13-14, 2001, in Nara, Japan. The technology of polymer science has developed considerably during the past half-century, and this volume describes some of the aspects of this technology that will have a great impact in the future. Among these advances, for example, are gene delivery to specific disease sites and carrier polymers that respond to a stimulus or particular environment. Cancer targeted drug delivery is another focused area of this volume because of the important nature of EPR-effect of polymer drugs in tumor. Included are discussions of as many examples as possible of polymer drugs that have achieved, or are close to clinical use. The concept of "Polymer drugs" here is limited to primarily injectable and water-soluble agents, although also covered are some drugs in micellar form or liposomes. This book is intended for students and researchers in the field of pharmacology who have particular interests in drug delivery, targeting, and formulation, as well as for clinicians such as oncologists who are interested in the field. People who work at regulatory agencies should also be aware such that drugs with great potential are being developed and will be beneficial to many patients, as well as to health insurance agencies because of improved cost effectiveness.